NervGen Pharma (TSXV:NGEN) 3-Year EBITDA Growth Rate : -2.60% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma 3-Year EBITDA Growth Rate?

NervGen Pharma's EBITDA per Share for the three months ended in Dec. 2023 was C$-0.14.

During the past 3 years, the average EBITDA Per Share Growth Rate was -2.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -33.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of NervGen Pharma was -0.80% per year. The lowest was -87.50% per year. And the median was -2.60% per year.

Competitive Comparison of NervGen Pharma's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, NervGen Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NervGen Pharma's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's 3-Year EBITDA Growth Rate falls into.

NervGen Pharma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

NervGen Pharma (TSXV:NGEN) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

NervGen Pharma 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma (TSXV:NGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

NGENF:USA 9UA:Germany

Address

2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6

Website

https://www.nervgen.com

NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.

NervGen Pharma (TSXV:NGEN) Headlines

No Headlines